Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting

2023-09-21

临床研究

- Three abstracts demonstrate new insights that can be derived from whole-transcriptome-based thyroid cancer molecular profiles - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting being held in Washington, DC from September 27 to October 1. Together, these abstracts offer novel insights into the molecular underpinnings of thyroid nodules and tumors based on whole-transcriptome RNA sequencing data from thyroid nodules analyzed with the Afirma GSC. “As we enter a new era in the personalized diagnosis and management of thyroid nodules and cancer, it is more important than ever to advance the science around this cancer so we can ultimately characterize each patient’s individual molecular profile,” said Joshua Klopper, MD, Veracyte’s medical director for Endocrinology. “The abstracts to be presented by our clinical research colleagues at the ATA meeting show that the Afirma GSC platform can be used to glean new insights about thyroid nodules and thyroid cancer preoperatively. We believe that Afirma-based whole-transcriptome analysis will help drive cancer research and unlock findings that may ultimately be used in clinical care.” The following late-breaking posters will be presented at the 2023 ATA Annual Meeting (all times ET): Title: Leveraging RNA Sequencing for Pre-Operative Immunophenotyping of BRAFV600E+ Thyroid Nodules Presenter: Jarod Olay, M.S., UCLA David Geffen School of Medicine Poster #: 502 Date/Time: September 28; 10:00 a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m. Title: Molecular Assessment of Isthmus Thyroid Carcinomas Presenter: Sina Jasim, M.D., Washington University in St. Louis Poster #: 501 Date/Time: September 28; 10:00 a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m. Title: Sodium Iodide Symporter (NIS) Expression in Cytologically Indeterminate and Malignant Thyroid Nodules Presenter: Prasana Santhanam, M.B.B.S., M.D., The Johns Hopkins University School of Medicine Poster #: 515 Date/Time: September 28; 10:00 a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m. These abstracts will later be published as an online supplement to Thyroid, the official journal of the ATA. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. For more information, please visit and follow the company on Twitter (@veracyte). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that Veracyte can help advance the science around thyroid cancer so we can ultimately characterize each patient’s individual molecular pro that Afirma analysis can help drive cancer research and unlock findings that may ultimately be used in clinical care. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on March 1, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended June 30, 2023. Copies of these documents, when available, may be found in the Investors section of our website at . These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise. Veracyte, the Veracyte logo and Afirma are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries. Veracyte delivers the Afirma Genomic Sequencing Classifier and TERT DNA analysis from its CLIA laboratory. These tests are not CE-IVD marked and have not been cleared or approved by the FDA; their performance characteristics were determined by Veracyte and they might be considered for Research Use Only in some markets. Please contact Veracyte for confirmation.